PDCD1 and non-small cell lung carcinoma: This may serve as a potential biomarker of clinical benefit in patients with NSCLC treated with antiprogrammed cell death protein 1 (PD-1) and antiprogrammed cell death-ligand 1 (PD-L1) agents (28).